Get the Stockscreener App
36.17
7.78%
-3.05
After Hours:
36.55
0.38
+1.05%
Harrow Inc stock is traded at $36.17, with a volume of 2.06M.
It is down -7.78% in the last 24 hours and down -21.47% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$39.22
Open:
$39.04
24h Volume:
2.06M
Relative Volume:
3.16
Market Cap:
$1.34B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-37.68
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-33.01%
1M Performance:
-21.47%
6M Performance:
-2.22%
1Y Performance:
+37.79%
1-Day Range:
$36.04
$39.23
1-Week Range:
$36.04
$54.40
52-Week Range:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
36.17 | 1.45B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - ADVFN Ltd
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossHROW - Nasdaq
Harrow Q4 Earnings Call Highlights - MarketBeat
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
Why Is Eye-Disease-Focused Harrow Stock Falling Today? - Benzinga
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday
Harrow Q4 2025 Earnings Report: Revenue $89.1M, Net Income $6.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
Harrow Health Posts Record 2025 Results, Sets 2026 Outlook - TipRanks
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):